IDL Diagnostics AB (publ) (STO:IDLDX)

IDL Diagnostics AB Financials Overview

Financials in millions SEK. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	54.54	53.11	57.44	43.04	36.99	12
Revenue Growth	-9.01%	-7.54%	33.45%	16.37%	208.32%	14180.95%
Gross Profit Gross Profit Growth	30.59	27.73	31.56	-2.1	-2.11	-5.05
Operating Income Operating Income Growth	-7.47	-10.72	-5.23	-60	-60.12	-50.82
Net Income Net Income Growth	-8.42	-12.15	-3.34	-59.3	-58.97	-50.03
Earnings Per Share EPS Growth	-0.04	-0.05	-0.01	-0.26	-0.27	-0.53
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024
Other Segments Other Segments Growth	0.08	0.08	0.11
Bacteriology Bacteriology Growth	30.43	29.58	35.64
Oncology Oncology Growth	24.03	23.46	21.68
Total Total Growth	54.54	53.11	57.44

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	37.33	36.57	47.79	50.72	65.19	18.4
Total Debt Total Debt Growth	12.69	13.24	15.3	-	-	-
Net Cash (Debt) Net Cash Growth	24.65	23.34	32.49	50.72	65.19	18.4
Net Cash Growth	-46.97%	-28.17%	-35.95%	-22.19%	254.25%	-56.25%
Net Cash Per Share Net Cash Per Share Growth	0.11	0.10	0.14	0.22	0.30	0.20

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	-4.85	-7.6	-0.43	-13.44	-13.69	-28.21
Capital Expenditures CapEx Growth	-0.68	-0.68	-2.07	-0.5	-3.02	-
Free Cash Flow Free Cash Flow Growth	-5.53	-8.27	-2.5	-13.93	-16.72	-28.21
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	56.08%	52.22%	54.95%	-4.88%	-5.69%	-42.06%
Operating Margin	-13.69%	-20.18%	-9.10%	-139.40%	-162.55%	-423.61%
Pretax Margin	-15.44%	-22.88%	-5.81%	-137.78%	-160.33%	-421.58%
Profit Margin	-15.43%	-22.88%	-5.81%	-137.78%	-159.45%	-417.01%
FCF Margin	-10.13%	-15.57%	-4.35%	-32.38%	-45.20%	-235.13%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 2, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PS Ratio	1.82	1.53	1.56	2.34	3.86	9.08

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 31, 2026

Data Sources Report a data error